Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 'Master protocol' aims to revamp cancer trials.

Literature DB >> 23765467

'Master protocol' aims to revamp cancer trials.

Heidi Ledford.

Abstract

Entities: Disease

Mesh：

Year: 2013 PMID： 23765467 DOI： 10.1038/498146a

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. A new model for reimbursing genome-based cancer care.

Authors: Scott D Ramsey; Sean D Sullivan
Journal: Oncologist Date: 2013-12-05

Review 2. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.

Authors: Edward B Garon; Phillip A Abarca; Jennifer L Strunck; Danielle Nameth; Catherine Neumann; Brian Wolf; Kevin Y Kim; Caitlin Marx; Robert M Elashoff
Journal: Crit Rev Oncog Date: 2015

3. Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Authors: Seung Tae Kim; Kyoung-Mee Kim; Nayoung K D Kim; Joon Oh Park; Soomin Ahn; Jae-Won Yun; Kyu-Tae Kim; Se Hoon Park; Peter J Park; Hee Cheol Kim; Tae Sung Sohn; Dong Il Choi; Jong Ho Cho; Jin Seok Heo; Wooil Kwon; Hyuk Lee; Byung-Hoon Min; Sung No Hong; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Woong-Yang Park; Jeeyun Lee
Journal: Oncologist Date: 2017-07-12

'Master protocol' aims to revamp cancer trials.

1. A new model for reimbursing genome-based cancer care.

Review 2. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.

3. Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Review 4. Advances in the management of paediatric high-grade glioma.

5. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.

Review 6. Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.

7. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

8. Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling.

9. The translation of cancer genomics: time for a revolution in clinical cancer care.

10. New generation of breast cancer clinical trials implementing molecular profiling.